Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

▤ Summary

Entrada Therapeutics said its independent safety committee cleared the company to start Cohort 2 of its ELEVATE-45-201 study at a higher 10 mg/kg dose. The study evaluates ENTR-601-45 as a potential treatment for Duchenne muscular dystrophy in patients with exon 45 skipping amenable mutations. Entrada said Cohort 1 participants have moved into the open-label Phase 2 portion of the trial, and it still expects to share Cohort 1 data in mid-2026. The company also outlined the planned progression through Cohorts 2 and 3 as it continues dose escalation and safety evaluation.

▦ Linked Companies